ATX-LPA receptor axis in inflammation and cancer

Shuying Liu, Mandi Murph, Nattapon Panupinthu, Gordon B. Mills

Research output: Contribution to journalReview articlepeer-review

74 Scopus citations

Abstract

Lysophosphatidic acid (LPA, 1- or 2-acyl-sn-glycerol 3-phosphate) mediates a plethora of physiological and pathological activities via interactions with a series of high affinity G proteincoupled receptors (GPCR). Both LPA receptor family members and autotaxin (ATX/LysoPLD), the primary LPA-producing enzyme, are aberrantly expressed in many human breast cancers and several other cancer lineages. Using transgenic mice expressing either an LPA receptor or ATX, we recently demonstrated that the ATX-LPA receptor axis plays a causal role in breast tumorigenesis and cancer-related inflammation, further validating the ATX-LPA receptor axis as a rich therapeutic target in cancer.

Original languageEnglish (US)
Pages (from-to)3695-3701
Number of pages7
JournalCell Cycle
Volume8
Issue number22
DOIs
StatePublished - Nov 15 2009
Externally publishedYes

Keywords

  • ATX
  • Breast cancer
  • Cytokines
  • G protein-coupled receptor
  • Inflammation
  • LPA
  • Target therapy

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'ATX-LPA receptor axis in inflammation and cancer'. Together they form a unique fingerprint.

Cite this